ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and
safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with
moderately to severely active ulcerative colitis who have inadequate response, no response, a
loss of response, or an intolerance to either conventional therapies [corticosteroids,
immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced
therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor
modulators, and/or JAK inhibitors].